Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOT-1010 versus bevacizumab with carboplatin + paclitaxel for advanced non-squamous non-small cell lung cancer
ChiCTR2500102299Phase 3Completed
- Sponsor
- Shanghai Chest Hospital
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HOT-1010 in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: Objective response rate at week 18. Started May 2025; status: completed.
02
Drugs
HOT-1010
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on ChiCTR2500102299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102299.